Association of apolipoprotein A-V with mRNA expression of IL-6 and NF-κB genes in type 2 diabetes with hypertriglyceridemia: a possible link with inflammation

  • Devesh Sharma
  • Seema GargEmail author
  • Mohit Mehndiratta
  • S. V. Madhu
  • Dinesh Puri
Original Article



Hypertriglyceridemia and inflammation are implicated in cardiovascular complications in type 2 diabetes mellitus (T2DM). While some studies have evaluated apolipoprotein A-V protein (Apo A-V) in diabetes and its effect on triglycerides (TG) levels, only a few have explored its relation with inflammatory markers.


To evaluate the expression of mRNA genes involved in inflammatory response (IL-6 and NF-κB) and to study their association with Apo A-V in patients of T2DM, with and without hypertriglyceridemia.


Two groups of T2DM patients, comprising of 40 participants each, were constituted according to NCEP ATP III criteria for CVD risk: group 1/controls (TG ≤ 1.65 mmol/l) and group 2/cases (TG ≥ 2.2 mmol/l). Serum levels of Apo A-V, free fatty acids (FFA) and IL-6 were estimated. Fold change in mRNA expression of IL-6 and NF-κB (p65) gene in blood was calculated by ΔΔCT method.


The mRNA expression of IL-6 and p65 was higher in cases. Significant inverse association of Apo A-V levels was observed with expression of p65 gene (p = 0.000) and IL-6 gene (p = 0.003) in all subjects. FFA levels also correlated inversely with the expression of p65 (p = 0.001) and IL-6 (p = 0.005) mRNA. The association of FFA levels and ApoA-V with mRNA expression of IL-6 and p65 genes was independent of each other.


This study highlights that inflammatory pathways are unregulated in hypertriglyceridemia in T2DM. Also, apart from its association with TG levels, Apo A-V may have an anti-inflammatory role as evident from its inverse association with the expression of IL-6 and NF-κB expression. Thus, Apo A-V may provide an important link between TGs, inflammation, and vascular complications in T2DM.


Apolipoprotein av., human Hypertriglyceridemia Type 2 diabetes mellitus Free fatty acids Nf kappa b p65 il6 



The authors convey their gratitude to the patients who participated in the study and to the technical staff of department of the Biochemistry and hospital lab services.


Apo A-V Apolipoprotein A-V protein

Apo A5 Apolipoprotein A5 gene

TG Triglycerides

T2DM Type 2 diabetes mellitus

IL-6 Interleukin 6

NF-κB Nuclear factor-kappa B

P65 Nuclear factor-kappa B gene

FFA Free fatty acids

Funding information

Project was funded by the intramural grant obtained from parent institution, University College of Medical Sciences.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Statement of informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox D, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169–73.CrossRefGoogle Scholar
  2. 2.
    Su X, Kong Y, Peng D. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients. Lipids Health Dis. 2018;17:174. Scholar
  3. 3.
    International Diabetes Federation. IDF Diabetes Atlas update poster, 6th edn. Brussels, Belgium: International Diabetes Federation, 2015.Google Scholar
  4. 4.
    Dallinga-Thie GM, van Tol A, Hattori H, Van Vark-van der zee LC, Jansen H, Sijbrands EJ, et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:1505–11.CrossRefGoogle Scholar
  5. 5.
    Pruneta-Deloche V, Ponsin G, Groisne L, Fruchart-Najib J, Lagarde M, Moulin P. Postprandial increase of plasma apoAV concentrations in type 2 diabetic patients. Atherosclerosis. 2005;181:403–5.CrossRefGoogle Scholar
  6. 6.
    Longo DL, Fauci A, Kasper D, Hauser S, Jameson JL, Loscalzo J. Diabetes mellitus. In: Harrison’s principles of internal medicine. 17th ed. Vol 2: McGraw-Hill; New York; 2008: p.2275–2304.Google Scholar
  7. 7.
    Grunfeld C, Dinarello CA, Feingold KR. Tumor necrosis factor alpha, interleukin-1, and interferon alpha stimulate triglyceride synthesis in HepG2 cells. Metabolism. 1991;40:894–8.CrossRefGoogle Scholar
  8. 8.
    National Cholesterol Education Program (NCEP) expert panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (adult TreatmentPanel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002 ;106:3143–3421.Google Scholar
  9. 9.
    Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241–8.CrossRefGoogle Scholar
  10. 10.
    Satoh J, Yagihashi S, Toyota T. The possible role of tumor necrosis factor-alpha in diabetic polyneuropathy. Exp Diabesity Res. 2003;4:65–71.CrossRefGoogle Scholar
  11. 11.
    Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;S18:1450–2.CrossRefGoogle Scholar
  12. 12.
    Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;101:42–7.CrossRefGoogle Scholar
  13. 13.
    Shi X, Chen Y, Nadeem L, Xu G. Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. J Neuroinflammation. 2013;10:69.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Genoux A, Gervois P, Rommens C, Dehondt H, Foulard M et al. Apolipoprotein A5 is an inflammatory responsive gene down-regulated by tumor necrosis factor alpha and interleukin-1. Athero supp. 2004(2).Google Scholar
  15. 15.
    Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.CrossRefGoogle Scholar
  16. 16.
    Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50:2792–808.CrossRefGoogle Scholar
  17. 17.
    Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev. 2003;124:495–502.CrossRefGoogle Scholar
  18. 18.
    Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res. 2005;46:2015–22.CrossRefGoogle Scholar
  19. 19.
    American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl 1):S11–66 Standards of Medical Care in Diabetes--2013.CrossRefGoogle Scholar
  20. 20.
    Sharma D, Garg S, Mehndiratta M, Madhu SV, Puri D. Hypertriglyceridemia in type 2 diabetes patients and its relationship with serum apolipoprotein A-V levels, oxidative stress and inflammatory markers. Int J Endocrinol Metab. 2017;15(2):e44805. Scholar
  21. 21.
    The IDF consensus worldwide definition of the metabolic syndrome. Available at: Accessed on April 18, 2016.
  22. 22.
    Norata GD, Catapano AL. Triglyceride-rich lipoproteins from hypetriglyceridemic subjects induce a pro-inflammatory response in the endothelium: molecular mechanisms and gene expression studies. J Mol Cell Cardiol. 2006;40:484–94.CrossRefGoogle Scholar
  23. 23.
    Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.PubMedGoogle Scholar
  24. 24.
    Cooke AA, Connaughton RM, Lyons CL, McMorrow AM, Roche HM. Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome. Eur J Pharmacol 2016;12.Google Scholar

Copyright information

© Research Society for Study of Diabetes in India 2019

Authors and Affiliations

  • Devesh Sharma
    • 1
  • Seema Garg
    • 2
    Email author
  • Mohit Mehndiratta
    • 1
  • S. V. Madhu
    • 3
  • Dinesh Puri
    • 1
  1. 1.Department of BiochemistryUniversity College of Medical Sciences, University of DelhiDelhiIndia
  2. 2.Department of BiochemistryAll India Institute of Medical SciencesNagpurIndia
  3. 3.Department of MedicineUniversity College of Medical Sciences, University of DelhiDelhiIndia

Personalised recommendations